Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD133 CAR-T cells
- Development stage
- Unknown
- Lead developer
- Century Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous, Intratumoral
01
Overview
CD133 CAR-T cells are an investigational chimeric antigen receptor (CAR) T-cell therapy designed to target CD133 (Prominin-1), a glycoprotein expressed on the surface of cancer stem cells and brain tumor-initiating cells (BTICs). Developed by researchers at McMaster University and the University of Toronto, this therapy utilizes a second-generation CAR construct incorporating a single-chain variable fragment (scFv) derived from the RW03 monoclonal antibody, linked to CD28 costimulatory and CD3ζ signaling domains. The therapy is intended to target and eliminate the CD133-positive cell populations that are often resistant to conventional chemotherapy and radiotherapy, thereby preventing tumor recurrence. Preclinical studies in glioblastoma models showed significant reductions in tumor burden and improved survival, supporting its advancement into Phase 1 clinical trials for patients with recurrent glioblastoma.
- Other names
- anti-CD133 CAR-T cellsanti-CD-133 CAR-T cellsanti-CD 133 CAR-T cellsCD133-specific CAR-T cellsCD-133-specific CAR-T cellsCD 133-specific CAR-T cells
02
Targets
CD133 (CD133 antigen)
Beyond the preview
Go deeper on CD133 CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD133 CAR-T cells.